PHAXIAM Therapeutics voluntarily delists ADSs from Nasdaq for deregistration under the Securities Exchange Act of 1934.
PHAXIAM Therapeutics, a biopharmaceutical company, announces the effectiveness of its voluntary delisting of American Depositary Shares (ADSs) from the Nasdaq Stock Market. The ADSs represent the company's ordinary shares, and the delisting process is part of PHAXIAM's plan to deregister ADSs under the Securities Exchange Act of 1934. The company will file a Form 15 to suspend reporting obligations and expects deregistration to be effective 90 days after filing.
March 11, 2024
3 Articles